GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Schott Pharma AG & CO KGaA (WBO:1SXP) » Definitions » Short-Term Debt

Schott Pharma AG KGaA (WBO:1SXP) Short-Term Debt : €0.0 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Schott Pharma AG KGaA Short-Term Debt?

Schott Pharma AG KGaA's Short-Term Debt for the quarter that ended in Dec. 2024 was €0.0 Mil.


Schott Pharma AG KGaA Short-Term Debt Historical Data

The historical data trend for Schott Pharma AG KGaA's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Schott Pharma AG KGaA Short-Term Debt Chart

Schott Pharma AG KGaA Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24
Short-Term Debt
0.58 - - - -

Schott Pharma AG KGaA Quarterly Data
Sep20 Sep21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Schott Pharma AG KGaA Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Schott Pharma AG KGaA Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Schott Pharma AG KGaA's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Schott Pharma AG KGaA Business Description

Traded in Other Exchanges
Address
Hattenbergstrasse 10, Mainz, RP, DEU, 55122
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.

Schott Pharma AG KGaA Headlines

No Headlines